Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Financial Results (Aug 1, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 1, 2024
Period End
August 1, 2024
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported second quarter 2024 results on August 1, 2024, as furnished under Item 2.02 of this Form 8-K (Exhibit 99.1 press release).

Total revenues for the quarter were $590.2 milliona, up from $452.7 million in the second quarter of 2023, with net product sales of INGREZZA at $583.8 million (the press release describes INGREZZA second quarter net sales as $580 million, growing 32% year over year). GAAP net income was $65.0 million, or $0.63 per diluted share, versus $95.5 million, or $0.95 per diluted share, a year earlier. Non-GAAP net income was $168.9 million, or $1.63 per diluted share, compared with $125.7 million, or $1.25, in the prior-year quarter.

GAAP results were affected by a $49.7 millionb charge tied to convertible senior notes conversion settlements, a $19.9 million loss on equity security investments, $27 million of development milestones expensed under collaborations, and a $14 million leased office impairment. The company raised its 2024 INGREZZA net product sales guidance to $2.25 billion to $2.3 billion. Updated 2024 expense guidance calls for GAAP R&D of $665 million to $695 million, non-GAAP R&D of $600 million to $630 million, GAAP SG&A of $955 million to $975 million, and non-GAAP SG&A of $830 million to $850 million.

Cash, cash equivalents and marketable securities totaled approximately $1.7 billionc at June 30, 2024 ($1,676.7 million), after a $309 million payment to fully retire the convertible senior notes. Leadership news is significant: CEO Kevin Gorman, Ph.D. will retire on October 11, 2024, and Kyle Gano, Ph.D., currently Chief Business Development and Strategy Officer, will succeed him and join the Board. The company also reported positive topline Phase 2 SAVITRI data for NBI-1065845 in major depressive disorder, FDA acceptance and Priority Review for crinecerfont in congenital adrenal hyperplasia with PDUFA dates of December 29 and 30, 2024, and Phase 2 top-line data for NBI-1117568 and luvadaxistat expected in Q3 2024.

Key Highlights

  1. Q2 2024 total revenues of $590.2 million vs. $452.7 million in Q2 2023; net product sales of $583.8 million vs. $446.3 million
  2. INGREZZA Q2 2024 net product sales of $580 million, up 32% year over year, driven by patient demand and improved gross-to-net dynamics
  3. GAAP diluted EPS of $0.63 vs. $0.95 a year earlier; non-GAAP diluted EPS of $1.63 vs. $1.25
  4. 2024 INGREZZA net product sales guidance raised to $2.25 billion to $2.3 billion
  5. CEO Kevin Gorman to retire October 11, 2024; Kyle Gano to succeed him as CEO and join the Board
  6. Crinecerfont NDAs for congenital adrenal hyperplasia accepted with Priority Review; PDUFA dates December 29 and 30, 2024
  7. Cash, cash equivalents and marketable securities of approximately $1.7 billion at June 30, 2024, after a $309 million payment to retire convertible senior notes

Frequently Asked Questions

  1. Why did GAAP earnings fall year over year while non-GAAP earnings rose?

    GAAP net income was $65.0 million versus $95.5 million in Q2 2023, reflecting a $49.7 million charge tied to convertible senior notes conversion settlements, a $19.9 million loss on equity security investments (compared with a $37.3 million gain a year earlier), $27 million of development milestones expensed under collaborations, and a $14 million leased office impairment. Non-GAAP net income excludes these items and stock-based compensation, rising to $168.9 million from $125.7 million, driven by higher INGREZZA sales and improved operating margin.

  2. What is the updated INGREZZA sales outlook for 2024?

    Neurocrine raised its 2024 INGREZZA net product sales guidance to a range of $2.25 billion to $2.3 billion, reflecting expected sales in tardive dyskinesia and chorea associated with Huntington's disease.

  3. Who will lead Neurocrine going forward?

    Chief Executive Officer Kevin Gorman, Ph.D., will retire on October 11, 2024. Kyle Gano, Ph.D., currently Chief Business Development and Strategy Officer, will succeed him as CEO and join the Board of Directors at that time. Dr. Gorman will continue to serve on the Board.

  4. What are the key regulatory and clinical catalysts mentioned?

    The FDA accepted NDAs for crinecerfont in adult and pediatric congenital adrenal hyperplasia and granted Priority Review, with PDUFA target action dates of December 29, 2024 (capsule) and December 30, 2024 (oral solution). Top-line Phase 2 data for NBI-1117568 and luvadaxistat are expected in Q3 2024, and the company is conducting an End of Phase 2 meeting with the FDA for NBI-1065845 ahead of planned Phase 3 studies in 2025.

  5. How strong is the balance sheet after the convertible note repayment?

    Cash, cash equivalents and marketable securities totaled approximately $1.7 billion at June 30, 2024 ($1,676.7 million), compared with $1,719.1 million at December 31, 2023. This figure reflects a $309 million payment to fully retire the convertible senior notes, which were settled in full in cash upon their May 15, 2024 maturity. Stockholders' equity was $2,509.2 million at June 30, 2024.